ABT vs BSX — Key Metrics

Metric ABT (ABBOTT LABORATORIES) BSX (BOSTON SCIENTIFIC CORP)
Price104.4843.64
Market Cap180.95 Billion63.26 Billion
P/E (TTM)38.8418.34
P/B (Quarterly)3.8752.506
P/S (TTM)3.753.0
Net Profit Margin (TTM)9.716.6
Gross Margin (TTM)56.969.1
ROE (TTM)9.013.9
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

ABBOTT LABORATORIES
vs
 
BOSTON SCIENTIFIC CORP
 
ABBOTT LABORATORIES
vs
 
BOSTON SCIENTIFIC CORP
Performance Comparison
AI Model Recommendation
ABT · ABBOTT LABORATORIES

Underperform

-42
UnderperformOutperform
BSX · BOSTON SCIENTIFIC CORP

Greatly Outperform

84
UnderperformOutperform
Recommendation Summary

Stock ABT is projected to underperform the market, stock BSX is projected to greatly outperform the market. Upfront Recommendation: BSX.

Financial Metrics
Prices delayed ~15 min
ABT Metrics BSX
$104.48 Price $43.64
— Market Capitalization —
38.84 Price to Earnings Ratio 18.34
3.75 Price to Sales 3.0
26.78 Price to FCF Ratio 18.99
6.59 Price to Gross Profit 4.34
54.6 Price to R&D 29.3
7.7 Price to Current Assets 7.75

ABT vs BSX at a glance

Abbott Laboratories (ABT) and Boston Scientific Corp (BSX) are both Medical Devices companies in the Healthcare sector. ABT is the larger, at $181.0 billion in market value against $63.3 billion for BSX, about 2.9 times the size.

On trailing-twelve-month figures, ABT trades at 38.8 times trailing earnings and BSX at 18.3; net profit margins are 9.7% and 16.6%.

The Upfront Investment model currently rates ABT Underperform and BSX Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.